Try our mobile app

Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Published: 2022-11-01 12:00:00 ET
<<<  go to KNSA company page

– ARCALYST®(rilonacept) Q3 2022 net revenue of $33.4 million– RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p